Swiss Hospitality Stock News

SWX:LUKN
SWX:LUKNBanks

Luzerner Kantonalbank (SWX:LUKN) Margin Strength Reinforces Bullish Narratives

Luzerner Kantonalbank (SWX:LUKN) has just wrapped up its Q1 2026 reporting period with trailing 12 month revenue of CHF660.6 million, basic EPS of CHF5.97 and earnings growth of 3.1% over the past year. Over the last year, revenue has moved from CHF650.5 million to CHF660.6 million, while net income excluding extra items has gone from CHF286.6 million to CHF295.5 million, with net profit margin edging up to 44.7% from 44.1%. This puts the focus firmly on how sustainably those margins can be...
SWX:ALSN
SWX:ALSNElectronic

A Look At ALSO Holding (SWX:ALSN) Valuation After Robust Westcoast Integration Progress

Westcoast integration gives investors fresh context for ALSO Holding ALSO Holding (SWX:ALSN) is back in focus after its acquired unit Westcoast reported a stronger first quarter in 2026 than in 2025, highlighting progress in integration, cloud operations and logistics synergies. See our latest analysis for ALSO Holding. Despite the positive integration news, ALSO Holding’s share price, at CHF147.4, sits well below where it started the year. It has a year to date share price return of 31.6%...
SWX:ABBN
SWX:ABBNElectrical

ABB (SWX:ABBN) Valuation Check As ETF Robotics Demand And Earnings Anticipation Drive Trading Activity

ABB (SWX:ABBN) has drawn attention after becoming one of the most actively traded stocks on the SIX Swiss Exchange, with ETF driven demand for robotics and automation coinciding with anticipation around its April 22 earnings update. See our latest analysis for ABB. At a share price of CHF70.8, ABB has seen a 7 day share price return of 7.53% and a year to date share price return of 15.61%. Its 1 year total shareholder return of 74.47% points to strong momentum that recent ETF flows and...
SWX:UBSG
SWX:UBSGCapital Markets

UBS Weighs US Bank Expansion Against Holocaust Legal Risks And Private Credit

UBS Group (SWX:UBSG) has secured approval for a US national banking licence, expanding its ability to offer banking services to US wealth management clients. A US court has declined to clarify the scope of a longstanding Holocaust era settlement involving UBS, leaving questions over potential future claims. UBS has executed a $500m private credit structured finance transaction backed by interests in private credit funds. UBS Group, trading at CHF32.41, is coming into these developments...
SWX:IFCN
SWX:IFCNElectronic

Assessing INFICON Holding (SWX:IFCN) Valuation After Q4 2025 Earnings Beat And Semiconductor Recovery Outlook

Q4 earnings beat puts INFICON Holding (SWX:IFCN) in focus INFICON Holding (SWX:IFCN) is back on investors’ radar after reporting a Q4 2025 earnings per share beat of 85.33% versus expectations, helped by cost controls and operational discipline despite a slight revenue miss. See our latest analysis for INFICON Holding. The Q4 surprise appears to be feeding into sentiment, with the 7 day share price return of 5.50% and a 1 day share price return of 1.27% lifting the stock to CHF111.2. A 1 year...
SWX:ROP
SWX:ROPPharmaceuticals

Should Roche’s Bet on Degrader-Antibody Conjugates and New HIV/Hepatitis Test Reshape Roche (SWX:ROP)?

C4 Therapeutics recently announced a collaboration with Roche to develop degrader-antibody conjugates for oncology, while Roche also launched its cobas MPX-E blood screening assay in CE-mark accepting countries, consolidating HIV and hepatitis virus detection into a single high-throughput test. Together, these moves underline Roche’s push to pair next-generation cancer modalities with advanced diagnostics that can improve laboratory efficiency and transfusion safety worldwide. We’ll now...
SWX:VACN
SWX:VACNMachinery

A Look At VAT Group (SWX:VACN) Valuation After Q1 2026 Sales Guidance Cut And Confirmed 2026 Outlook

VAT Group (SWX:VACN) updated investors after cutting first quarter 2026 sales guidance to around CHF 215 million following supply chain disruptions, while reiterating that full year 2026 metrics are expected to be higher than 2025 levels. See our latest analysis for VAT Group. Despite the revised first quarter guidance, VAT Group’s recent trading has stayed firm, with a 7 day share price return of 9.15% and a 90 day share price return of 20.40%. The 1 year total shareholder return of 95.41%...
SWX:ALC
SWX:ALCMedical Equipment

Is Alcon (SWX:ALC) Offering Value After A 15.5% One Year Share Price Decline?

If you are wondering whether Alcon's current share price reflects its true worth, the recent performance offers some clear signals to unpack. The stock last closed at $61.00, with a 1.1% gain over the past week, a 3.3% decline over 30 days, and returns of 4.0% decline year to date and 15.5% decline over the past year. These moves sit against a backdrop where investors have been reassessing medical equipment names and updating their expectations for companies like Alcon. Sector sentiment...
SWX:LOGN
SWX:LOGNTech

Assessing Logitech International (SWX:LOGN) Valuation After Recent Share Price Weakness

Logitech International stock: understanding recent performance Logitech International (SWX:LOGN) has drawn investor attention after a recent pullback, with the share price showing a 3.4% decline over the past day and a 1.7% move lower over the past week. See our latest analysis for Logitech International. That short term weakness sits against a mixed backdrop, with the 90 day share price return of 6.8% decline and a year to date share price return of 9.3% decline contrasting with a 1 year...
SWX:NOVN
SWX:NOVNPharmaceuticals

A Look At Novartis (SWX:NOVN) Valuation After Fabhalta Phase III IgA Nephropathy Results

Novartis (SWX:NOVN) is back in focus after releasing final two year Phase III data for Fabhalta in IgA nephropathy, which showed clinically meaningful kidney outcomes versus placebo and supports an ongoing FDA priority review. See our latest analysis for Novartis. The Fabhalta readout appears to be feeding into sentiment, with the share price at CHF122.18 and a 90 day share price return of 7.14%. The 1 year total shareholder return of 48.62% contrasts with a more modest 12.61% year to date...
SWX:RSGN
SWX:RSGNElectrical

R&S Group Holding (SWX:RSGN) Revenue Jump Tests Bullish Earnings Narratives

R&S Group Holding (SWX:RSGN) has reported its FY 2025 figures with first half revenue of CHF 206.3 million and basic EPS of CHF 0.77, set against trailing twelve month revenue of CHF 417.7 million and EPS of CHF 1.56 that reflect a 41% earnings increase over the last year. The company has seen revenue move from CHF 172.7 million in the second half of FY 2024 to CHF 206.3 million in the first half of FY 2025, with EPS shifting from CHF 0.86 to CHF 0.77 in those respective periods. This leaves...
SWX:JFN
SWX:JFNTransportation

Assessing Jungfraubahn Holding (SWX:JFN) Valuation After Full Year 2025 Results And Higher Dividend

Jungfraubahn Holding (SWX:JFN) has just released full year 2025 results together with a higher annual dividend, giving investors fresh information on earnings, cash returns and how the business exited last year. See our latest analysis for Jungfraubahn Holding. The share price reaction has been positive in the short term, with a 5.1% 1 day share price return and 5.7% 7 day share price return. The 1 year total shareholder return of 69.1% reflects much stronger gains over a longer period. If...
SWX:SWON
SWX:SWONElectronic

SoftwareOne (SWX:SWON) Trims Dividend Amid New HR Chief Appointment – What Is Management Prioritizing Now?

SoftwareOne Holding AG has released its 2025 results, reporting sales of CHF 1,243.4 million and net income of CHF 0.9 million, while proposing a reduced CHF 0.15 per share dividend and setting 2026 guidance for mid-single digit constant-currency revenue growth and a 30%–50% adjusted profit pay-out ratio. Alongside these figures, the company announced a leadership change in human resources, with long-time insider Nina Janorschke stepping in as Chief Human Resources Officer, which may help...
SWX:ROG
SWX:ROGPharmaceuticals

A Look At Roche (SWX:ROG) Valuation After The New Cobas MPX E Assay Launch

Roche’s new cobas MPX-E assay and why it matters for shareholders Roche Holding (SWX:ROG) has launched its cobas MPX-E multiplex assay in CE mark countries, offering simultaneous screening for HIV, HCV, HBV and HEV on existing cobas x800 systems to support higher throughput donor testing. See our latest analysis for Roche Holding. Roche’s share price has softened recently, with a 30 day share price return of 10.47% and a year to date share price return of a 0.98% decline, even though the 1...
SWX:OFN
SWX:OFNCommercial Services

European Dividend Stocks To Watch In April 2026

As European markets experience a positive shift, with the STOXX Europe 600 Index gaining 3.92% amid hopes for a shorter-lived Middle East conflict, investors are keenly observing how energy market volatility and inflation trends might impact dividend stocks. In this context, selecting robust dividend stocks involves considering companies with strong financial health and stable cash flows that can weather economic fluctuations while continuing to provide reliable income streams.
SWX:BCGE
SWX:BCGEBanks

A Look At Banque Cantonale De Genève (SWX:BCGE) Valuation After Its Latest Dividend Increase

Dividend announcement puts yield in focus for BCGE Banque Cantonale de Genève (SWX:BCGE) has announced an annual dividend of CHF 0.5250 per share, with the stock trading ex dividend on 5 May 2026 and payment scheduled for 7 May 2026. See our latest analysis for Banque Cantonale de Genève. The dividend news follows a strong run in the shares, with a 30 day share price return of 12.38% and a 90 day share price return of 40.48%. The 1 year total shareholder return of 48.30% highlights how...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Pricing In The Credit Suisse Integration And Recent Share Performance?

If you are wondering whether UBS Group's current share price reflects its true worth, you are not alone. That is exactly what this article is here to unpack. UBS Group closed at CHF31.16 recently, with returns of 1.4% over the past 7 days, 4.4% over the past 30 days, a year to date return of negative 18.4%, 39.6% over 1 year, 79.1% over 3 years and 141.6% over 5 years, hinting at shifting expectations around both opportunity and risk. Recent coverage has focused on UBS Group's ongoing...